Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Astrazeneca plc symbols : Cgen save search
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Published: 2024-01-08 (Crawled : 12:00) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 2.29%
H: 8.38%
C: 4.47%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.28%
H: 0.99%
C: 0.93%
first million payment astrazeneca cancer trial milestone
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Published: 2023-12-19 (Crawled : 12:30) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 178.08%
H: 21.18%
C: -1.48%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.5%
H: 0.99%
C: 0.43%
first payment astrazeneca cancer trial milestone
Compugen Reports Third Quarter 2023 Results
Published: 2023-11-07 (Crawled : 12:00) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: -5.83%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.59%
H: 0.46%
C: -0.09%
results
Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3
Published: 2023-02-14 (Crawled : 17:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 3.85%
H: 5.86%
C: 2.36%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.3%
H: 0.94%
C: 0.6%
com902 antibody expected
Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902
Published: 2021-10-04 (Crawled : 14:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 0.5%
H: 4.17%
C: 0.83%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.28%
H: 0.83%
C: 0.82%
milestone
Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development
Published: 2021-08-19 (Crawled : 11:00) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: -1.67%
H: 3.91%
C: -1.36%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.54%
H: 1.13%
C: 0.12%
antibody
Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products
Published: 2020-12-23 (Crawled : 18:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 4.37%
H: 0.88%
C: -8.78%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.78%
H: 0.02%
C: -0.69%
license antibody milestone
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
ASNS | $0.828 21.75% 17.86% 18K
|
UONE | $2.36 19.8% 16.53% 75K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.